Payment overview · 2025
General Payments
$40,866.01
178 reported records · 23 companies
Healthcare provider profile · identity verified
Mark K Jenson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GREEN BAY, WI · NPI 1598727000
Verified facts
What the public records show
CMS Open Payments records show Mark K Jenson, M.D. received $40,866.01 in general payments during 2025 across 178 reported records.
Takeda Pharmaceuticals U.S.A., Inc. accounted for 94.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $38,405.36 | 94.0% | 63 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $322.40 | 0.8% | 17 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $214.04 | 0.5% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $172.41 | 0.4% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $169.92 | 0.4% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $161.95 | 0.4% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $161.84 | 0.4% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $158.85 | 0.4% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $155.53 | 0.4% | 9 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $144.85 | 0.3% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $138.77 | 0.3% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $92.85 | 0.2% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $78.30 | 0.2% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $76.68 | 0.2% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $73.64 | 0.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $68.18 | 0.2% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $66.09 | 0.2% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $63.13 | 0.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.45 | 0.1% | 3 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $25.14 | 0.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.03 | 0.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.04 | 0.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.56 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $37,347.10 | 36 |
| Food and Beverage | $2,595.34 | 122 |
| Travel and Lodging | $923.57 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $229.17 | 12 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $191.08 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $162.85 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $161.95 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $161.84 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $158.85 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $157.85 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $145.78 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $145.78 | 8 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $144.85 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $141.33 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $138.77 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $138.77 | 8 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $134.69 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $119.29 | 6 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $115.60 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $115.60 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $107.54 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $92.85 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $82.49 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $78.30 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $76.68 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $66.09 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.80 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $43.79 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $41.30 | 2 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $33.11 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.65 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.65 | 2 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $25.14 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.15 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $12.07 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $12.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 63 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 53 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
63 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
63 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 485 | 132 |
| Omeprazole | Omeprazole | 303 | 81 |
| Metformin Hcl | Metformin Hcl | 301 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 294 | 78 |
| Meloxicam | Meloxicam | 270 | 79 |
| Furosemide | Furosemide | 260 | 84 |
| Prednisone | Prednisone | 260 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 251 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 250 | 66 |
| Gabapentin | Gabapentin | 244 | 53 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 240 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 217 | 55 |
| Simvastatin | Simvastatin | 169 | 46 |
| Irbesartan | Irbesartan | 167 | 46 |
| Lisinopril | Lisinopril | 156 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 151 | 50 |
| Celecoxib | Celecoxib | 144 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 144 | 48 |
| Losartan Potassium | Losartan Potassium | 141 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 38 |
| Tramadol Hcl | Tramadol Hcl | 119 | 24 |
| Finasteride | Finasteride | 112 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 108 | 27 |
| Alprazolam | Alprazolam | 105 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 32 |
| Atenolol | Atenolol | 102 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 31 |
| Allopurinol | Allopurinol | 90 | 27 |
| Diazepam | Diazepam | 90 | 19 |
| Potassium Chloride | Potassium Chloride | 87 | 26 |
| Amoxicillin | Amoxicillin | 84 | 61 |
| Warfarin Sodium | Warfarin Sodium | 79 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 77 | 56 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 14 |
| Sertraline Hcl | Sertraline Hcl | 74 | 20 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 72 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 19 |
| Januvia | Sitagliptin Phosphate | 68 | 16 |
| Valsartan | Valsartan | 66 | 16 |
| Cephalexin | Cephalexin | 65 | 31 |
| Eliquis | Apixaban | 63 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 20 |
| Glimepiride | Glimepiride | 60 | 20 |
| Memantine Hcl | Memantine Hcl | 60 | 13 |
| Donepezil Hcl | Donepezil Hcl | 57 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | suppressed |
| Baclofen | Baclofen | 55 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 17 |
| Jardiance | Empagliflozin | 53 | 11 |
| Trazodone Hcl | Trazodone Hcl | 51 | 15 |
| Mupirocin | Mupirocin | 49 | 27 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Azithromycin | Azithromycin | 47 | 38 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 30 |
| Montelukast Sodium | Montelukast Sodium | 45 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 13 |
| Metformin Hcl Er | Metformin Hcl | 44 | 12 |
| Bumetanide | Bumetanide | 43 | 15 |
| Ezetimibe | Ezetimibe | 42 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | suppressed |
| Xarelto | Rivaroxaban | 40 | 11 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | suppressed |
| Fenofibrate | Fenofibrate | 38 | 11 |
| Lovastatin | Lovastatin | 38 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 34 | 15 |
| Famotidine | Famotidine | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 13 |
| Glipizide | Glipizide | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Carvedilol | Carvedilol | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 27 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Nucynta Er | Tapentadol Hcl | 12 | suppressed |
| Quinine Sulfate | Quinine Sulfate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Amjevita(Cf) Autoinjector | Adalimumab-Atto | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Xiidra | Lifitegrast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $40,866.01 · 178 records | Takeda Pharmaceuticals U.S.A., Inc. | ABRYSVO, ACTHAR, AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, Dyanavel XR, ELIQUIS, FANAPT, FREESTYLE LIBRE, GEMTESA, INGREZZA, JARDIANCE, Jornay PM, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TRINTELLIX, TRUMENBA, The Cologuard Plus Collection Kit, UBRELVY, VYNDAQEL, Wegovy, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error